Sirolimus alone for low platelet counts from antiphospholipid antibodies
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had positive antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, or anti-b2GP1) on at least two tests taken 12 weeks apart.
- Your platelet count has been between 30 and 100 billion per liter for at least 2 weeks.
- If you take prednisone or similar steroids, the dose must be less than 10 mg per day and stable for at least 2 weeks.
- If you take hydroxychloroquine, the dose must be less than 400 mg per day and stable for at least 1 month.
- You must not have taken certain other platelet-raising or immune-suppressing drugs (like romiplostim, intravenous immunoglobulin, rituximab) for a period equal to 5 times their half-life before starting.
- You do not have other connective tissue diseases (like lupus), active infections, major bleeding, recent clots, or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This study tests whether sirolimus (an immune-calming drug) is safe and helpful for people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. If you join, you'll get either sirolimus or a placebo alongside your usual treatment, to see if it reduces clotting problems.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial tests a low dose of sirolimus, a medicine that may help your bone marrow make more blood cells, especially platelets. It is for people with a specific genetic change (RUNX1) that affects blood cell production.
This trial tests whether a low dose of sirolimus, a drug that calms the immune system, can help improve blood counts and reduce bleeding risk in people with a genetic condition called RUNX1 familial platelet disorder. If it works, it might lower the chance of developing serious blood problems later.
Hear when a new Thrombocytopaenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.